AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04967534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.
Study NCT04967534 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: social contact control group
Description: Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
Study NCT06115447 — intervention group
Intervention type: PROCEDURE
Intervention: lung suturing with polyglactin
Description: lung suturing with polyglactin
Study NCT06115447 — intervention group
Intervention type: PROCEDURE
Intervention: ung suturing with polypropylene
Description: ung suturing with polypropylene
Study NCT05724329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Dasatinib + Quercetin (neoadjuvant)
Description: Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Study NCT05724329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Standard of care
Study NCT05724329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Dasatinib + Quercetin (adjuvant)
Description: Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
Study NCT05208060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV130
Description: Treatment administered sublingually
Study NCT05208060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment administered sublingually
Study NCT06601114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol Group
Description: Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days
Study NCT06601114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen group
Description: Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
Study NCT04838405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: Synthetic Peptide
Study NCT04838405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05893485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy Intervention
Description: Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
Study NCT05023551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0390
Description: DSP-0390 administered orally
Study NCT04793360 — intervention group
Intervention type: DEVICE
Intervention: LiverCare
Description: The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
Study NCT05424406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active phototherapy
Description: Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.
Study NCT05424406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control phototherapy
Description: Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.
Study NCT05424406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
Study NCT05424406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep education control
Description: Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
Study NCT05557110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Reduced-intensity chemotherapy followed by Blinatumomab
Study NCT06350643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Health Block Culturally Tailored training
Description: This online course will be developed for healthcare providers and will fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by Health Disparities and Lung Cancer Screening (HDLCS) training.
Study NCT06350643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Disparities and Lung Cancer Screening training
Description: The Health Disparities and Lung Cancer Screening training is an online course that covers disparities in lung cancer and smoking, patient barriers to lung cancer screening, and provider resources for addressing common barriers.
Study NCT05048134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300
Description: HRS2300 monotherapy
Study NCT05048134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300、 SHR-1316
Description: HRS2300 combined with SHR-1316
Study NCT05048134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300、SHR-1701
Description: HRS2300 combined with SHR-1701
Study NCT05048134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300、trametinib
Description: HRS2300 combined with trametinib
Study NCT05048134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300、Almonertinib
Description: HRS2300 combined with Almonertinib
Study NCT04730609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
Study NCT04300192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT06236802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProVee device
Description: ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
Study NCT06173323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPart - Improving Chronic Kidney Disease Decisional Partnerships
Description: ImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience.
Study NCT06653907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Sodium (LT4) Tablets
Description: Participants in our study will determine the dosage of L-T4 based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH > ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery.
Study NCT06653907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in our study will determine the dosage of placebo based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH > ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery.
Study NCT05510583 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
Study NCT05510583 — intervention group
Intervention type: OTHER
Intervention: Treated group
Description: Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
Study NCT06654479 — intervention group
Intervention type: OTHER
Intervention: In the newborns in the study, changes in body temperatures during routine nursing interventions of the nurses of the clinic were examined.
Description: The study is an observational study. The newborns were not intervened by the researcher. Body temperature changes were observed during routine practices of nurses in the clinic.
Study NCT06654973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMP-produced SARS-CoV-2 Delta strain
Description: The challenge virus used in Sing-CoV study is the same as that used in COVHIC002 study. It was originally obtained in mid 2021 from a nose-throat swab from an otherwise healthy young adult with mild COVID-19 in the community. The procedure for isolation, storage, preparation, and administration of challenge virus in this study (Sing-CoV and COVHIC002) is the same as used in the first SARS-CoV-2 human challenge study (COVHIC001) at Imperial College London and the same as used in the COV-CHIM01 (NCT04864548) SARS-CoV-2 human challenge study at University of Oxford.
Study NCT06603324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVVHD treatment in paediatric mode with multiFiltratePRO
Description: Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO
Study NCT06594536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane
Study NCT06594536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo
Study NCT06599242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy
Description: Basic Body Awareness Therapy is an exercise approach belonging to physiotherapists
Study NCT06599242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American football team training
Description: American football team training
Study NCT06599242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American football team training
Description: American football team training
Study NCT06597643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Training
Description: Exercise 1: Eccentric Wrist Extension with Dumbbell~Position: Seated, elbow extended, wrist maximally extended.~Action:~Lower: Slowly flex the wrist for 30 seconds. Return: Use the opposite hand to bring wrist back to extension. Load: Increase weight based on 10 Repetition Maximum (10RM). Exercise 2: Eccentric Wrist Extension with Twist-Bar~Position: Hold Flex Bar with involved hand in extension.~Action:~Twist: Rotate the bar with the non-involved hand while keeping the involved wrist extended.~Untwist: Allow the wrist to flex slowly. Exercise 3: Eccentric Supination with Elastic Band~Position: Anchor band, elbow flexed to 90°.~Action:~Supinate: Rotate forearm with palm up. Flex: Slowly rotate to palm down, then return
Study NCT06597643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: Exercise 1: Eccentric Wrist Extension with Dumbbell~Position: Seated, elbow extended, wrist maximally extended.~Action:~Lower: Slowly flex the wrist for 30 seconds. Return: Use the opposite hand to bring wrist back to extension. Load: Increase weight based on 10 Repetition Maximum (10RM). Exercise 2: Eccentric Wrist Extension with Twist-Bar~Position: Hold Flex Bar with involved hand in extension.~Action:~Twist: Rotate the bar with the non-involved hand while keeping the involved wrist extended.~Untwist: Allow the wrist to flex slowly. Exercise 3: Eccentric Supination with Elastic Band~Position: Anchor band, elbow flexed to 90°.~Action:~Supinate: Rotate forearm with palm up. Flex: Slowly rotate to palm down, then return
Study NCT06597643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Friction Massage
Description: The patient will sit on a chair while holding a pillow. DFM will be performed in perpendicular direction to the Extensor carpi radialis brevis tendon the site of the application will be on the upper attachment of the common extensor origin (palpated one cm distal to the lateral epicondyle of the humerus) for 5 minutes. Using the thumb, Firm pressure will be applied to compress the extensor tendons, their origins, and the musculotendinous junctions between the underlying bone and the fingertips. This pressure will be maintained while the therapist applies DFM in the direction of their fingers,
Study NCT06602843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
Description: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
Study NCT06602843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
Description: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
Study NCT06588972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglyceride solution
Description: Placebo
Study NCT06588972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Group 2: C. sativa extract with THC:CBD ratio 1:10 (2mg:20mg/day);
Study NCT06588972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis Sativa
Description: Group 3: C. sativa extract with THC:CBD ratio 1:10 (4mg:40mg/day).
Study NCT06596824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training intervention
Description: Personalized digital training intervention aims to correct pathological knee movement and loading patterns and reduce inflammation in pre-stage knee osteoarthritis.
Study NCT06589817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochloride Carliprazine capsules
Description: Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
Study NCT06589817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablets
Description: Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
Study NCT06594341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visit frequency
Description: Fortnightly visit frequency for moderate phase~Nutritional supplement: 1 daily sachet of RUTF as soon as a child admitted with MUAC\<115mm or edema reaches a MUAC=>115mm or absence of edema.
Study NCT06594341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Suppression of the transition period
Description: Transitioning children admitted with MUAC\<115mm or edema to receiving 1 daily sachet of RUTF as soon as they reach a MUAC=>115mm and absence of edema
Study NCT06594341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simplified treatment
Description: Admitting children with MUAC\<125mm or edema to treatment prescribing 2 daily sachets for children with MUAC\<115mm or edema and 1 daily sachet for children with MUAC 115mm to 124mm. Treatment visits are done on a weekly basis and children with MUAC\<115mm are transitioned to receiving 1 daily sachet of RUTF once they reach a MUAC=>115mm for 2 consecutive measurements. Treatment is continued until recovery defined as a MUAC=>125mm for 2 consecutive weeks.
Study NCT06594341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified treatment
Description: Admitting children with MUAC\<125mm or edema to treatment prescribing 2 daily sachets for children with MUAC\<115mm or edema and 1 daily sachet for children with MUAC 115mm to 124mm. Treatment visits are done on a weekly basis and children with MUAC\<115mm are transitioned to receiving 1 daily sachet of RUTF once they reach a MUAC=>115mm for 2 consecutive measurements. Treatment is continued until recovery defined as a MUAC=>125mm for 2 consecutive weeks.
Study NCT06604013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical full-mouth periodontal therapy without using adjunct disinfectants
Description: Supragingival scaling was performed by Ultrasonic Scaler and manual scaling by sickle scaler . Subgingival scaling and root planing were accomplished with either universal or area specific Gracey curettes
Study NCT06604013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: GCF level of adiponectin and resistin
Description: Gingival crevicular fluid (GCF) samples were gathered and relocated in phosphate buffer saline inside Eppendorf tube then t they were manipulated by commercially available enzyme-linked immuno-sorbent assay
Study NCT06231342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscope (DL)
Description: DL allows visualization of the larynx. It is used during general anesthesia, for surgical procedures of the larynx, and during resuscitation.
Study NCT06591442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: This is an observational study
Description: This study divides the elderly population into two groups: the Elderly group and the Advanced age group. By observing the enhanced recovery after spinal fusion surgery in these two distinct age groups of elderly patients, risk factors affecting postoperative enhanced recovery will be identified. Detection index: Blood routine examination, blood biochemistry, coagulation function, imaging examination (X-ray, CT 3D reconstruction), Japanese Orthopaedic Association (JOA) score, visual analogue scale (VAS) pain score. The number of participants for all adverse events, serious adverse events, implant-related adverse events and drug-related serious adverse events, and the adverse events were summarized accordingly. The severity of adverse events will be rated according to NCI-CTCAE version 4.0.
Study NCT06592898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: straight leg raise
Description: The patient was supine position, one knee angle was 90°, the foot was flatted on the ground. The ankle was flexed to contract the quadriceps on the other side. Then straighten the knee joint and the hip was 30° and lift the thigh, the heel was about 20cm away from the ground, and put down the lower limb after 2 seconds. Ten times are in a group, each practice has 5 groups, rest between the groups is 1 minute. Practice 5 times a week, practice on both sides, take uniform respiration without holding breath.
Study NCT06592898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wall squat
Description: The subjects' upper body was upright, the distance between feet was same as width of shoulder, and hands were placed on each side of the body or above the thighs. Tiptoes were towards the front, and perpendicular to the wall. The distance between the wall and heel was about a foot long, and the back was close to the wall, squatted slowly.